Lancet oncol: Effects of preoperative radiotherapy on prognosis in patients with postmenal sarcoma.

Unlike sarcoma in the limbs, the efficacy of radiotherapy for post-permainal sarcoma is not yet clear.
study aims to assess the effects of preoperative radiotherapy combined surgery and simple surgery on the recurrence of re-occurrence prognosis in patients with abdominal sarcoma.
EORTC-62092 is an open-label, randomized Phase 3 trial conducted at 31 medical research centers in 13 countries in Europe and the United States, in which subjects were biogenicly diagnosed, removable, radiotherapy-like local, primary peritonal sarcoma patients who had not been treated in the past, who performed 0-2 points, according to 1:1 to two groups.
therapy dose is 50.4Gy.
mainly assessed the endpoint as the survival rate of recurrence-free in the abdomen.
January 18, 2012 - April 10, 2017, 266 patients were recruited, 133 in each group.
43.1 months (IQR 28.8-59.2).
128 (96%) of the patients who underwent pure surgery were operated on, and 119 (89%) of the combined radiotherapy group underwent radiotherapy and surgery.
recurrence-free life of the abdomen in the combined surgical group and in the simple surgical group was 4.5 years and 5.0 years (HR 1.01,95% CI 0.71-1.44, p-0.95), respectively.
most common level 3-4 adverse reactions were lymphocyte reduction (77% vs. 1% in the single surgical group), anemia (12% vs 8%) and hypoglobinemia (12% vs 4%).
30 (24%) and 13 (10%) severe adverse reactions occurred in the joint group and the single surgical group, respectively.
patients in the joint group died from treatment-related severe adverse reactions (gastric thoracic fistula), and none of the patients in the single surgical group died from treatment-related adverse reactions.
results above, preoperative radiotherapy is not considered as a standard treatment for patients with postmenal sarcoma.
.